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Physical therapy and deep brain
stimulation in Parkinson’s Disease: protocol
for a pilot randomized controlled trial
Ryan P. Duncan1,2* , Linda R. Van Dillen1,3, Jane M. Garbutt4,5, Gammon M. Earhart1,2,6 and Joel S. Perlmutter1,2,6,7,8
Abstract
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) reduces tremor, muscle stiffness, and bradykinesia
in people with Parkinson’s Disease (PD). Walking speed, known to be reduced in PD, typically improves after surgery;
however, other important aspects of gait may not improve. Furthermore, balance may worsen and falls may increase
after STN-DBS. Thus, interventions to improve balance and gait could reduce morbidity and improve quality of life
following STN-DBS. Physical therapy (PT) effectively improves balance and gait in people with PD, but studies on the
effects of PT have not been extended to those treated with STN-DBS. As such, the efficacy, safety, and feasibility of PT in
this population remain to be determined. The purpose of this pilot study is to address these unmet needs. We
hypothesize that PT designed to target balance and gait impairment will be effective, safe, and feasible in this population.
Methods/design: Participants with PD treated with STN-DBS will be randomly assigned to either a PT or control group.
Participants assigned to PT will complete an 8-week, twice-weekly PT program consisting of exercises designed to
improve balance and gait. Control group participants will receive the current standard of care following STN-DBS, which
does not include prescription of PT. The primary aim is to assess preliminary efficacy of PT on balance (Balance Evaluation
Systems Test). A secondary aim is to assess efficacy of PT on gait (GAITRite instrumented walkway). Participants will be
assessed OFF medication/OFF stimulation and ON medication/ON stimulation at baseline and at 8 and 12 weeks after
baseline. Adverse events will be measured over the duration of the study, and adherence to PT will be measured to
determine feasibility.
Discussion: To our knowledge, this will be the first study to explore the preliminary efficacy, safety, and feasibility of PT
for individuals with PD with STN-DBS. If the study suggests potential efficacy, then this would justify larger trials to test
effectiveness and safety of PT for those with PD with STN-DBS.
Trial registration: NCT03181282 (clinicaltrials.gov). Registered on 7 June 2017.
Keywords: Parkinson’s disease, Deep brain stimulation, Physical therapy, Balance, Gait
Background
Subthalamic nucleus deep brain stimulation (STN-DBS)
effectively reduces tremor, rigidity, and bradykinesia in
people with Parkinson’s Disease (PD) [1]. The annual
number of STN-DBS procedures for PD totals between
8000 and 10,000 [2] and will likely rise in the near future
[3]. Despite the spread of this new treatment modality,
the effect on postural instability and gait is unclear.
Postural stability initially improves following STN-DBS
[4–6]; however, these benefits may not endure. For ex-
ample, postural responses worsened in individuals
6 months post-DBS surgery [7], and STN-DBS did not
improve balance in individuals with PD who had abnor-
mal quiet stance prior to surgery [8]. Further, STN-DBS
initially improves postural instability and gait difficulty
(PIGD), but 2 years after surgery, these deficits were
worse than before surgery [9]. Also, falls may increase
after STN-DBS surgery [10]. STN-DBS effectively
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improves gait spatial parameters (e.g., stride length), but
may not change temporal parameters. Stride-to-stride
variability, known to be impaired [11] in PD, did not
change following STN-DBS [12]. More importantly, ap-
proximately 42% of individuals post-STN-DBS subject-
ively reported worsened gait [13]. Deficits in balance and
gait may lead to falls, fall-related complications, and
physical inactivity in people with PD [14]. These
negative effects may lead to a “malignant” form of PD
with reduced quality of life and increased mortality [14].
Physical therapy (PT) effectively complements
pharmacologic interventions to improve postural stabil-
ity and gait in people with PD who do not have DBS
[15–18]. Given the potential for worsening of balance
and gait following STN-DBS, PT may be an effective ad-
junct treatment to optimize long-term outcomes after
STN-DBS surgery. However, no studies to date have
assessed the impact of PT for those with PD who have
STN-DBS as these individuals are frequently excluded
from exercise trials [18–23]. Although the current stand-
ard of care permits return to exercise within weeks fol-
lowing STN-DBS, there is no explicit call for PT [24]. As
such, the efficacy, safety, and feasibility of exercise in this
population remain to be determined.
The primary purpose of this study is to examine the
preliminary efficacy of PT on balance in people with PD
with STN-DBS. We chose balance as the primary out-
come because balance is most likely to remain impaired
after surgery [7, 8]. Secondarily, we will examine the pre-
liminary efficacy of PT on gait as well as safety and feasi-
bility of the intervention in this population in people
with PD with STN-DBS. We hypothesize that partici-
pants assigned to PT will 1) demonstrate improvements
in balance and gait while controls will not change, 2) not
experience more adverse events than those in the con-
trol group, and 3) complete at least 80% of prescribed
PT sessions.
Methods/design
This pilot study is designed as a randomized controlled
trial. Participants will be randomly assigned (1:1 ratio) to
either the PT intervention group or control group in a
consecutive fashion. Randomization will be stratified by
the participant’s medication and stimulation condition
for their first visit to the laboratory. Using an internet
randomization scheme generator (http://www.graphpad.
com/quickcalcs/randomize1.cfm), a study team member
will write the group assignment number (i.e., 1 = PT, 2 =
Control) on a piece of paper wrapped in tin foil. This
will be placed in an opaque envelope and sealed. The
study team member conducting these procedures will
have no role in scheduling participants, data collection,
or assigning participants to the intervention. After
participants complete both pre-test assessments (see
detailed information below), they will be allowed to open
the envelope to determine their group assignment.
Participants
All participants will be at least 30 years of age and meet
the following inclusion criteria: 1) neurologist diagnosed
idiopathic PD [25–27] between Hoehn and Yahr (H&Y)
stages II–IV (measured on stimulation and medication),
2) at least 1-year post-STN-DBS, 3) able to attend assess-
ment sessions, and 4) able to provide informed consent.
Participants will be excluded if they have any of the fol-
lowing: 1) diagnosis of atypical parkinsonism, 2) H&Y
stages I or V, 3) evidence of dementia (i.e., Mini-Mental
Status Exam (MMSE) score ≤ 24/30 [28]), or 4) inability to
walk 10 m with or without an assistive device. Written in-
formed consent will be obtained from each participant in
accordance with the policies and procedures of the
Washington University Human Research Protection
Office (approved November 9, 2016; IRB ID: 201609148).
Intervention
PT intervention
Participants assigned to PT will attend a 1-h visit with
a physical therapist (RPD) twice weekly for 8 weeks and
will also complete an individualized home exercise pro-
gram twice weekly. The PT intervention, which will
mirror traditional PT for those with PD [15], will
include exercises designed to improve balance, gait, and
lower extremity strength. PT will be provided in the
outpatient physical therapy clinical practice at the
Washington University Program in Physical Therapy.
In addition to the PT intervention, those assigned to
the PT group will receive the current standard of care,
defined as clinical optimization by the neurologist of
STN-DBS parameters and anti-PD medication.
Postural stability exercises will follow the framework
provided by Schoneburg and colleagues [29], targeting
quiet stance, anticipatory and reactive postural adjust-
ments, and dynamic postural control. Balance exercises
following a similar framework improved balance and re-
duced falls in people with PD without STN-DBS [18]. A
detailed protocol of the postural stability exercises has
been developed to enhance reproducibility and guide
decision-making for exercise progression. Exercise per-
formance will be evaluated each visit and progressed ac-
cording to rules set forth in the PT intervention
protocol (see Additional file 1). The starting level for
each exercise level will be commensurate with each par-
ticipant’s ON medication/ON stimulation baseline
BESTest performance. Gait exercises will include tread-
mill walking and dual-task gait training with the goal of
improving spatiotemporal gait parameters. Both tread-
mill walking [30, 31] and dual-task gait training [32, 33]
have been used to reduce gait variability and improve
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spatiotemporal gait parameters in people with PD
without DBS.
Home exercise program
A home exercise program (HEP), to be performed twice
weekly, will be prescribed at the participant’s initial visit
with the physical therapist. The HEP incorporates the
following lower extremity functional movements: sit-to-
stand, heel raises, hip flexion, and standing half squats.
The HEP is designed to address biomechanical con-
straints related to balance performance. A detailed HEP
protocol will enhance reproducibility and guide exercise
progression. Performance of the HEP will be reviewed
weekly, and progression will be determined based on
participant performance according to rules set forth in
the HEP protocol (see Additional file 2).
Control group
As in the PT group, participants in the control group
will receive the current standard of care (i.e.,
optimization of STN-DBS parameters and anti-PD medi-
cation as needed) following STN-DBS. However, those
in the control group will not receive prescribed exercise
from a physical therapist.
Assessments
All participants will undergo the same battery of balance
and gait tests. Although STN-DBS settings are typically
stable at 12 months post-surgery, participants will follow
up with their neurologists as needed for programming
and medication adjustments throughout the study. All
changes in programming settings and medication
dosages will be noted. Participants will be tested in the
following conditions: 1) OFF stimulation and OFF
medication and 2) ON stimulation and ON medication.
Testing participants OFF stimulation/OFF medication
will allow us to determine if the addition of PT after
STN-DBS affects balance and gait independent of other
treatments. OFF medication is defined as greater than or
equal to 12 h since the last intake of anti-PD medication.
For OFF stimulation/OFF medication testing, partici-
pants will arrive at the laboratory OFF medication but
with stimulators on. The stimulators will be turned OFF
upon arrival at the laboratory and testing will commence
45 min after [34] the stimulators are turned OFF.
Testing ON stimulation/ON medication will provide
insight into how participants perform on an everyday
basis. ON medication is defined as 1–1.5 h after medica-
tion intake. For ON stimulation/ON medication assess-
ments, participants will arrive at the laboratory 1–1.5 h
after taking their normal anti-PD medication dose with
stimulators on and stimulators will remain on through-
out the session.
Assessments will occur at baseline and at 8 weeks (i.e.,
post-test) and 12 weeks after baseline (i.e., 12-week fol-
low up) (Fig. 1). A rater, blinded to group assignment,
will collect outcomes at each time point. Assessments
will take place on two separate days, and the order of
testing condition (OFF medication/OFF stimulation vs.
ON medication/ON stimulation) will be randomized.
The Movement Disorders Society—Unified Parkinson’s
Disease Rating Scale III (MDS-UPDRS III) [35], a gold-
standard measure of PD motor severity, will be adminis-
tered in each condition.
Primary outcome
Efficacy
Preliminary efficacy of the 8-week intervention on balance
will be assessed using the 27-item Balance Evaluation
Systems Test (BESTest). The BESTest [36] is a clinical
assessment of balance that has a total possible score of
108 points, with higher scores indicating better balance.
The BESTest is highly reliable [37] in people with PD.
Secondary outcomes
Efficacy
Preliminary efficacy of the intervention on gait will be
assessed with a GAITRite (CIR Systems, Sparta, NJ) to
measure spatiotemporal gait parameters (i.e., gait vel-
ocity, stride length, and stride-to-stride variability). This
Fig. 1 Diagram depicting participant recruitment, randomization,
assessments, and intervention
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is a 5-m computerized walkway that contains pressure
sensors and maps footfalls during walking. Average gait
velocity, stride length, and stride-to-stride variability will
be collected over five trials of preferred-pace forward
walking.
We also will collect an abbreviated battery of out-
comes each week throughout the 8-week PT interven-
tion to determine the response to PT and whether or
how this changes over the study period. The battery will
consist of the following measures: 10-m gait speed,
Timed Up and Go [38], and single-limb stance time.
Safety
At the baseline visit, all participants will be fully
instructed on what constitutes an adverse event. For this
study, an adverse event is defined as “any untoward or
unfavorable medical occurrence in a human subject, in-
cluding any abnormal sign (for example, abnormal phys-
ical exam or laboratory finding), symptom, or disease,
temporally associated with the subject’s participation in
the research, whether or not considered related to the
subject’s participation in the research.” [39]. Weekly calls
to participants will be conducted by the research coord-
inator to track any adverse events. Participants will be
asked questions related to falls, orthopedic injuries, un-
scheduled visits to a physician, or hospital admissions.
Furthermore, participants will be instructed to call a
member of the study team as soon as possible after an
adverse event. We will also monitor adverse events dir-
ectly related to the intervention. Adverse events may or
may not be determined as serious. Serious adverse
events are defined as unanticipated problems that 1)
would involve risks to participants, 2) relate or possibly
relate to participation in the research, and 3) suggest the
research places participants at greater risk of harm than
previously known or recognized. Examples of potential
serious adverse events are a fall with serious injury (e.g.,
fracture and head injury) or a major cardiac event. If the
serious adverse event occurs during an intervention ses-
sion or during performance of the HEP, it will be deter-
mined that it is directly related to the intervention. Our
a priori threshold for serious adverse events that would
constitute not moving forward with this intervention in
a larger trial is greater than one serious adverse event.
Feasibility
Feasibility will be measured by adherence to the PT
intervention and will be assessed in two ways. First,
participation in PT sessions will be tracked allowing
for calculation of a total percentage of PT sessions
attended. Second, adherence to the home exercise
program (HEP) will be tracked using a log-book in
which participants record a number of sets and repe-
titions completed for each exercise. This will be
reviewed weekly with the physical therapist. To pro-
mote adherence, participants who miss a PT session
will be phoned immediately after the missed appoint-
ment by the research coordinator to remind them of
their next appointment and urge them to continue
their HEP. Our a priori threshold for adherence to
the intervention which would constitute not moving
forward with this intervention in a larger trial would
be less than an average of 80%. This 80% threshold is
the typical adherence rate for short-term exercise pro-
grams in PD [40].
We will also measure PD motor severity and quality of
life. The MDS-UPDRS III [35], the gold-standard meas-
ure of motor sign severity, will be used to determine if
PT impacts motor sign severity in people with STN-DBS
when compared to the current standard of care. Quality
of life will be measured using the Parkinson’s Disease
Questionnaire-39 [41].
Data analysis
For intervention effects on balance and gait, the
BESTest total score and all gait variables (i.e., gait
velocity, stride length, and stride-to-stride variability)
will be analyzed using repeated measures analysis of
variance to test for main effects of group (PT, con-
trol) and time (baseline, 8 weeks, 12 weeks) and
group × time interactions (α = 0.05).
For safety, the total number of adverse events will be
reported for each group allowing for qualitative compar-
isons. For feasibility, adherence will be reported for both
attendance to PT sessions and HEP completion. Both
will be expressed as percent of sessions completed.
Power analysis
To our knowledge, there are no intervention studies that
specifically examined the efficacy of physical therapy on
balance in people with PD with STN-DBS. Given that
this is a pilot study, the authors chose an effect size that
would be meaningful and required to support moving
forward with a larger trial. As such, with a medium ef-
fect size of 0.25 (Cohen’s f ) [42] and an alpha level of
0.05, 14 participants per group will provide 82% power
to detect significant differences between or within
groups for the primary outcome (i.e., BESTest). Factor-
ing in the potential for a 20% attrition rate based on
prior studies, we plan to recruit 17 participants per
group. Point estimates and variance around the point es-
timates for the change in balance and gait will be used
to power a larger trial if the results support the hypoth-
eses. This pilot study is not powered to detect significant
differences in the number of adverse events between
groups, which is declared as a limitation.
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Discussion
This pilot study has several strengths. First, the random-
ized design helps to control for the effect of potential
unmeasured confounders on the outcomes of interest.
Second, blinded assessments will control for potential
rater bias. Third, testing people OFF medication/OFF
stimulation allows for determination of change after the
intervention in the absence of optimal medical and sur-
gical management. Testing participants ON medication/
ON stimulation allows for determination of change in
motor performance in the setting of optimal pharmaco-
logical and surgical management. Finally, the detailed
intervention protocol (See Additional files 1 and 2) de-
livered by a single physical therapist will enhance
standardization, reproducibility, and treatment fidelity.
Historically, studies of physical interventions in PD lack
the necessary information to accurately reproduce the
treatment. It is our hope that the depth of detail and de-
cision algorithm provided will reduce the ambiguity en-
countered when attempting to determine how and when
it was decided that treatment would be progressed.
While this study has several strengths, some weak-
nesses exist. First, the proposed small sample size limits
the ability to generalize our results to a larger popula-
tion. However, because this is a pilot study, the results
may provide the preliminary data to justify a larger ran-
domized controlled trial. Second, people less than 1-year
post-STN-DBS will be excluded to minimize the poten-
tial for changes in DBS programming. If the study re-
sults support our hypotheses, future studies could
evaluate the efficacy of PT for balance and gait deficits
before and/or immediately post-surgery, increasing the
potential impact of this research. Finally, only those with
STN-DBS will be included to maximize sample homo-
geneity in this pilot trial. In the future, investigators also
may study those with DBS in other brain locations (e.g.,
globus pallidus internus).
As PT is not currently part of the standard of care for
those with STN-DBS, the results, if in support of the
hypotheses, may lend initial support to the addition of
PT into the standard plan of care for these individuals.
Additionally, this preliminary work has the potential to
generate many future research questions. Data from this
study could be used to further explore how parameters
of exercise dose (i.e., intensity, frequency, duration) can
be best modified to optimize mobility-related outcomes
in those with STN-DBS. If our results indicate efficacy
of PT in this population, investigators may study the
benefits of PT prior to STN-DBS and determine if PT
modifies the trajectory of motor disability over time. In
sum, this work represents the start of a line of research
that could challenge current clinical practice paradigms
in the management of those with PD with STN-DBS.
Physical therapy is a personalized intervention that may
be useful to address specific movement impairments that
remain even when patients are on optimal regimens of
medication and STN-DBS.
Data monitoring
A Data and Safety Monitoring Board has not been for-
mally established as the intervention is considered to be
low risk. All adverse events will be reported to the prin-
cipal investigator (RPD). These will be reviewed on a
monthly basis with the study team (RPD, LVD, JSP,
GME, and JG) to determine if adverse events are or are
not related to the intervention and whether the trial
should be discontinued on the basis of safety problems.
Trial status
This trial was registered on clinicaltrials.gov (NCT:
03181282) on June 7, 2017. Recruitment of participants
was initiated on July 12, 2017. Accounting for attrition,
34 participants (17 per group) will be recruited to par-
ticipate in the study. With an expected inclusion rate of
three to four participants per month, an estimated re-
cruitment period of 12 months is required beginning
from the start of recruitment.
Dissemination of results
The study results will be shared through a peer-reviewed
manuscript and through conference presentations.
Additional files
Additional file 1: Physical therapy for deep brain stimulation: in-clinic
treatment program. (DOCX 35 kb)
Additional file 2: Physical therapy for deep brain stimulation: home
exercise program. (DOCX 14 kb)
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